Journal Thoracic Oncology

Abstracts Journal of Thoracic Oncology • Volume 12 Issue S1 January 2017
online) platform that allows for custom-weighted analyses. We used this tool
to compare progress against NSCLC with other tumor types when different
weights are assigned to different treatment contexts and goals. Results:
When assigning the largest weights to advanced and/or metastatic disease,
NSCLC has seen the most progress (i.e. E-Score increase) over the past 30 years
among the 12 common tumor types included in the tool. When focusing on
progress against early stage disease and in the adjuvant context, however,
NSCLC loses its top position to breast cancer. In both analyses, evidence
for treatments that increase survival begins to accumulate in the 1990s
and accelerates in the early 2000s, partly driven by the advent of targeted
treatments. Conclusion: The global fight against cancer is a very substantial
societal investment, and being able to track progress in specific domains will
likely be critical for focusing this endeavor. To account for the complexity of
the disease, progress cannot be summarized by a single metric. We here show
how the PACE CII can help obtain a multi-faceted, complex picture of progress
across the entire spectrum of tumor complexity and based on varying
patient values. We encourage the field to use this public database to conduct
additional analyses based on individual interests and preferences.
Keywords: evidence, progress, NSCLC, innovation
Copyright © 2016 by the International Association for the Study of Lung Cancer
S759